Leerink Swann reissued their buy rating on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research note released on Monday morning. They currently have a $182.00 target price on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on ALXN. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a research report on Thursday, September 14th. They set an outperform rating and a $161.00 price objective for the company. J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a neutral rating to an overweight rating and lifted their price objective for the stock from $163.00 to $175.00 in a research report on Tuesday, September 5th. BMO Capital Markets reiterated an outperform rating and set a $173.00 price objective (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Deutsche Bank AG reiterated a buy rating and set a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. reiterated a buy rating and set a $180.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $157.21.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 139.45 on Monday. The stock’s 50 day moving average is $139.14 and its 200 day moving average is $124.77. The firm has a market cap of $31.12 billion, a PE ratio of 60.47 and a beta of 1.40. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. The firm had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.13 EPS. On average, equities analysts forecast that Alexion Pharmaceuticals will post $5.60 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Leerink Swann Reaffirms “Buy” Rating for Alexion Pharmaceuticals, Inc. (ALXN)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/28/leerink-swann-reaffirms-buy-rating-for-alexion-pharmaceuticals-inc-alxn.html.

In related news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now directly owns 5,480 shares in the company, valued at $799,038.80. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock worth $2,416,869 over the last three months. 4.35% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in ALXN. Guardian Life Insurance Co. of America lifted its position in Alexion Pharmaceuticals by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Alexion Pharmaceuticals during the 1st quarter worth approximately $111,000. Fiduciary Trust Co. acquired a new position in Alexion Pharmaceuticals during the 2nd quarter worth approximately $111,000. Huntington National Bank lifted its position in Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 987 shares in the last quarter. Finally, Penserra Capital Management LLC lifted its position in Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 144 shares in the last quarter. 94.17% of the stock is currently owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.